BRD4 and MYB inhibition overcomes venetoclax resistance in EVI1-rearranged acute myeloid leukemia

Abstract EVI1-rearranged acute myeloid leukemia (AML) with inv(3)(q21q26) or t(3;3)(q21q26) represents a distinct and aggressive subtype characterized by poor prognosis and limited treatment options. However, the optimal strategy to overcome resistance to conventional therapy remains elusive. Buildi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Weijia Zang, Yui Koike, Koutarou Nishimura, Atsushi Tanaka, Hiromi Yamazaki, Takaya Yamasaki, Hiromi Ito, Yifan Zhang, Yumi Aoyama, Wataru Saika, Muran Xiao, Chihiro Hasegawa, Hiroyoshi Kunimoto, Hideaki Nakajima, Fumihiko Ishikawa, Akifumi Takaori-Kondo, Daichi Inoue
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Portfolio 2025-10-01
Schriftenreihe:Scientific Reports
Schlagworte:
Acute myeloid leukemia
EVI1
Venetoclax
Hypomethylating agent
MYB
BRD4
Online Zugang:https://doi.org/10.1038/s41598-025-21034-1
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge